HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

NCT06770452 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Pancreatic Carcinoma

Interventions

DRUG: HRS-4642
DRUG: Nimotuzumab
DRUG: gemcitabine + nab-paclitaxel

Sponsor

Zhejiang University